Meghalaya Magazine

The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market

 Breaking News
  • No posts were found

The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market

October 06
13:30 2021
The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market
Chemotherapy-Induced Anemia
Due to increased research initiatives and an increase in global healthcare spending, the dynamics of the Chemotherapy-Induced Anemia market are expected to change in the coming years.

DelveInsight’s Chemotherapy-Induced Anemia market report examines historical and projected epidemiology and Chemotherapy-Induced Anemia market trends in the 7MM. The Chemotherapy-Induced Anemia market report also analyzes current Chemotherapy-Induced Anemia treatment practices/algorithms, Chemotherapy-Induced Anemia market drivers, Chemotherapy-Induced Anemia market barriers, and unmet medical needs.

Some of the Important Findings from the Chemotherapy-Induced Anemia Market Report

  • Anemia is a common complication of both cancer treatment and the disease itself.
  • Leading pharmaceutical companies such as FibroGen and others are working diligently to develop novel therapies for Chemotherapy-Induced Anemia.
  • Key Chemotherapy-Induced Anemia therapies in the pipeline include Roxadustat and others.
  • Roxadustat (FibroGen) is a prolyl hydroxylase inhibitor of hypoxia-inducible factor (HIF-PHI) that promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and decreasing hepcidin.
  • The increase in Chemotherapy-Induced Anemia market size directly results from the growing incident population of Chemotherapy-Induced Anemia patients in the 7MM.

For more insights into the emerging treatment options, request for the sample @ Chemotherapy-Induced Anemia Market Outlook

Chemotherapy-Induced Anemia Overview

In oncology patients, anemia is the most common and persistent hematological abnormality. Chemotherapy-Induced Anemia (CIA) is caused by malignant invasion of normal tissue, which results in blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency due to inflammation.

Chemotherapy-Induced Anemia Epidemiology Segmentation

The Chemotherapy-Induced Anemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Ten Major Cancer Indications’ Incidence Cases
  • Incidence of Ten Major Cancer Indications with Chemotherapy-Induced Anemia
  • Chemotherapy-Induced Anemia Severity-Specific Incident Cases
  • Chemotherapy-Induced Anemia Diagnosed and Treatable Cases

Chemotherapy-Induced Anemia Therapeutics Market

The primary goals of Chemotherapy-Induced Anemia treatment are to relieve symptoms and improve quality of life. Current Chemotherapy-Induced Anemia treatment includes packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation. 

Find out which company is going to grab the maximum market share @ Chemotherapy-Induced Anemia Market Share

Chemotherapy-Induced Anemia Market Outlook

The dynamics of the Chemotherapy-Induced Anemia market are expected to change in the coming years due to increased research initiatives and an increase in global healthcare spending.

The expected launch of Roxadustat by leading pharma company FibroGen will fuel the growth of the Chemotherapy-Induced Anemia market during the forecast period (2021–30).

Chemotherapy-Induced Anemia Pipeline Therapies and Key Companies

  • Roxadustat: FibroGen 

Table of Contents 

1.

Key Insights

2.

Chemotherapy-Induced Anemia: Market Overview at a Glance

3.

Executive Summary

4.

Disease Overview: Chemotherapy-Induced Anemia

5.

Chemotherapy-Induced Anemia Epidemiology and Patient Population

6.

Chemotherapy-Induced Anemia Treatment and Management

7.

Organizations

8.

Patient Journey

9.

Case Studies

10.

Chemotherapy-Induced Anemia Emerging Therapies

11.

Key Cross Competition

12.

Chemotherapy Induced Anemia: 7 Major Market Analysis

13.

KOL Views

14.

Chemotherapy-Induced Anemia Market Drivers

15.

Chemotherapy-Induced Anemia Market Barriers

16.

Chemotherapy-Induced Anemia Market Access

17.

SWOT Analysis

18.

Chemotherapy-Induced Anemia Unmet Needs

19.

Bibliography

20.

Appendix

21.

Disclaimer

22.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Chemotherapy-Induced Neutropenia Market

Get a comprehensive analysis of Chemotherapy-Induced Neutropenia pipeline therapies and key companies such as Amgen, Kyowa Hakko Kirin Co., Ltd., Teva B.V., G1 Therapeutics, Spectrum Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/